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Abstract: Thioalbamide, a thioamidated peptide biosynthesized by Amycolatopsis alba, is a
thioviridamide-like molecule, and is part of a family of natural products representing a focus
of biotechnological and pharmaceutical research in recent years due to their potent anti-proliferative
and cytotoxic activities on malignant cells. Despite the high antitumor potential observed at nanomolar
concentrations, the mechanisms underlying thioalbamide activity are still not known. In this work, the
cellular effects induced by thioalbamide treatment on breast cancer cell lines were evaluated for the first
time, highlighting the ability of this microbial natural peptide to induce mitochondrial dysfunction,
oxidative stress, and apoptotic cell death. Furthermore, we demonstrate that thioalbamide can inhibit
the propagation of cancer stem-like cells, which are strongly dependent on mitochondrial function
and are responsible for chemotherapy resistance, metastasis, and tumor recurrence.
Keywords: thioviridamide-like molecules; RiPPs; natural products; anticancer agent; cancer stem cells
1. Introduction
Thioalbamide (Figure 1), a recently identified natural product [1], is biosynthesized by Amycolatopsis
alba DSM 44262, and belongs to the family of ribosomally synthesized and post-translationally
modified peptides (RiPPs). This class of natural products is generated by a series of post-translational
modifications occurring to a precursor peptide by the action of pathway-specific enzymes, which
are encoded in a gene cluster [2]. Precursor peptides can undergo a wide range of post-translational
modifications, resulting in mature RiPPs with peculiar chemical structures and biological activities,
which spark wide interest from the pharmaceutical point of view. In particular, thioalbamide belongs
to the thioviridamide-like molecules (TLMs), a family of compounds recently identified thanks to
genome mining studies [1,3] following the initial activity-guided discovery of thioviridamide [4].
The chemical peculiarity of this class of molecules is the presence of different thioamide groups in the
peptide backbone, a feature rarely found in natural products [5,6].
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Recent tudies have shown that TLMs display antiproliferative and cytotoxic effects in different
tumor cell lines [7,8], and in particular, thioalbamide has been shown to have activity at nanomolar
concentrations against breast, pancreatic, alveolar, and cervical cancer cells [1]. Interestingly,
thioalbamide displayed selective cytotoxic activity against tumor cells, but is less active against
non-tumor cell lines. Despite the powerful biological activity shown by TLMs, the biological
mechanisms responsible for their action have never been elucidated. The objective of this study was
to investigate, for the first time, the biological effects induced by thioalbamide in order to gain new
insights on the TLMs’ mode of action. In particular, we explored the mechanisms of cellular death
induced by this compound in breast cancer cell lines. Additionally, since we found that thioalbamide
was able to impair mitochondrial bioenergetics, we investigated if it was able to target cancer stem-like
cells (CSCs) considering that they are highly dependent on mitochondrial function for their clonal
expansion and survival [9]. CSCs are a subset of cancer cells that are highly resistant to current
therapeutic strategies, and are believed responsible for tumor recurrence and metastasis [10]. In this
context, thioalbamide is revealed to be a promising natural agent that is able to affect tumorigenicity of
breast CSCs.
2. Materials and Methods
2.1. Cell Cultures
All breast cell lines used in this work (MCF7, T47D, SKBR3, MDA-MB-231, MDA-MB-468,
and MCF10A) were purchased from the American Culture Collection (ATCC, Manassas, VA, USA).
Normal fibroblast BJ-hTERT cells were kindly provided by Professor Diego Sisci, University of Calabria,
Italy. MCF7 and MDA-MB-231 cells were cultured in DMEM/F12 (Sigma Aldrich, St. Louis, MO,
USA) supplemented with 10% Fetal Bovine Serum (FBS, Sigma Aldrich), 2 mM l-glutamine (Gibco,
Life Technologies, Waltham, MA, USA), and 1% penicillin/streptomycin (Gibco, Life Technologies).
MDA-MB-468 cells were cultured in DMEM (High Glucose) (Sigma Aldrich) supplemented with
10% FBS, 2 mM l-glutamine, and 1% penicillin/streptomycin. SKBR3 cells were cultured in RPMI
supplemented with 10% FBS, 2 mM l-glutamine, and 1% penicillin/streptomycin. T47D cells were
cultured in RPMI supplemented with 0.2 U/mL insulin (Gibco, Life Technologies) 10% FBS, 2 mM
l-glutamine, and 1% penicillin/streptomycin. MCF10A cells were cultured in DMEM/F12 supplemented
with 5% horse serum (HS, Sigma Aldrich), 10 mg/mL insulin (Sigma Aldrich), 0.5 mg/mL hydrocortisone
(Sigma Aldrich), 20 ng/mL human epidermal growth factor (hEGF, Sigma Aldrich), 0.1 mg/mL cholera
toxin (Sigma Aldrich), 2 mM l-glutamine, and 1% penicillin/streptomycin. BJ-hTERT were cultured in
DMEM (Sigma Aldrich) supplemented with 1% penicillin/streptomycin, 2 mM l-glutamine, and 10%
FBS. Treatments were performed in the above-mentioned media containing a lower amount of serum
(2%). All cell lines were cultured at 37 ◦C in 5% CO2 in a humidified atmosphere. Thioalbamide was
produced by the fermentation of A. alba DSM 44262 and then purified as described previously [1].
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2.2. Cell Viability Assay
Cell viability was determined by using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide (MTT) assay, as previously described [11]. Briefly, cells were seeded in 48-well plates with a
density of 2 × 104 cells/well and cultured in complete medium overnight. Cells were then treated with
increasing concentrations of previously purified thioalbamide [1] or doxorubicin (Sigma Aldrich) for
72 h, and Dimethyl Sulfoxide (DMSO) was used as the vehicle control. At the end of the treatment,
MTT solution was added to each well (to a final concentration of 0.5 mg/mL) and plates were incubated
at 37 ◦C for 2 h until the formation of formazan crystals. DMSO-solubilized formazan in each well
was quantified by absorbance at 570 nm using a microplate reader. Non-linear regression analysis
(GraphPad Prism 7) was used to generate sigmoidal dose-response curves to calculate IC50 values for
each cell line.
2.3. Cell Morphology Analysis
MCF7 cells were seeded into 6-well plates at a density of 1 × 105 cells/well and cultured
overnight in complete medium. Then, cells were treated with 50 nM thioalbamide for 72 h or DMSO
(control cells), then cells were subjected to phase-contrast light microscopy analysis or fixed and
stained with May Grünwald-Giemsa (Bio-Optica), as previously described [12]. Images at different
magnifications were taken with an Olympus BX41 microscope with CSV1.14 software using CAMXC-30
for image acquisition.
2.4. Cell Cycle Analysis
Cell cycle analysis was performed as previously described [13] with minor changes. MCF7 cells,
seeded in 6-well plates at a density of 1× 105 cells/well, were treated with DMSO or 50 nM thioalbamide
for 72 h. After treatment, cells were collected by trypsinization, washed twice with chilled PBS, and
spun at 1500 rpm for 5 min. Cells were fixed by re-suspending the pellets in 70% ethanol for 30 min at
4 ◦C. Cells were washed twice with PBS and stained in 3.8 mM sodium citrate, 50 µg/mL propidium
iodide (PI), 100 µg/mL RNAse, and 0.1% Igepal in PBS for 1 h at 37 ◦C. Samples were subjected to
cytofluorimetric analysis using BD FACSJazz™Cell Sorter (Becton Dickinson, Franklin Lakes, NJ, USA).
2.5. Immunoblot Analysis
For immunoblot analysis, cells were grown to 70–80% confluence and treated with 50 nM
thioalbamide or DMSO for 24–72 h. For preparation of total cell lysates, cells were harvested and
lysed in 200 µL of lysis buffer, as previously described [14]. For cytosolic fraction isolation, cells were
mechanically-lysed in isolation buffer for cells (IBC) (10 mM Tris/MOPS, 1 mM EDTA/Tris, 200 mM
sucrose, pH 7.4) using a glass potter homogenizer and lysates were centrifuged at 12,000 rpm for 20 min.
Supernatants and pellets were collected as cytosolic and mitochondrial fractions, respectively. The same
amounts of proteins from total lysate or cytosolic fractions were resolved on SDS-polyacrylamide gel,
transferred to a nitrocellulose membrane, and probed with appropriate primary antibodies (Santa Cruz,
Biotechnology, Dallas, TX, USA). To confirm equal loading and transfer, membranes were stripped
and incubated with the anti-GAPDH antibody (Santa Cruz, Biotechnology). The antigen-antibody
complex was detected by incubation of the membranes with peroxidase-coupled goat anti-mouse or
goat anti-rabbit antibodies and revealed using the ECL System (Bio-Rad Laboratories, Hercules, CA,
USA) [15]. The blots were then exposed to film, and the bands of interest were quantified by using
ImageJ software.
2.6. Terminal Deoxynucleotidyl Transferase-Mediated Deoxyuridine Triphosphate Nick End-Labeling
(TUNEL) Assay
Fragmentation of DNA, a late event during apoptosis, was determined by enzymatic labelling of
DNA strand breaks using terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate
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nick end-labeling (TUNEL). TUNEL labeling was conducted using TUNEL assay kit (Promega, Madison,
WI) on cells treated for 72 h with DMSO or 50 nM thioalbamide, according to the manufacturer’s
instructions. Nuclear staining was performed by using 0.2 mg/mL 4′,6- diamidino-2-phenylindole
(DAPI; Sigma Aldrich) and samples were analyzed with a fluorescent microscope (Olympus BX4 with
CSV1.14 software using a CAMXC-30 for image acquisition).
2.7. AnnexinV-PI Assay
Phospatidilserine externalization on the outer leaflet of the cell membrane was detected by the
AnnexinV-PI assay, according to the manufacturer’s protocols (Annexin V, Alexa FluorTM 488 conjugate
kit, Thermo Fisher Scientific). Briefly, 1 × 105 MCF7 cells were seeded in 6-well plates and treated with
50 nM thioalbamide for 24 h. After treatment, cells were collected, rinsed with PBS, and incubated
with FITC-AnnexinV and 100 µg/mL propidium iodide in 1× AnnexinV buffer for 15 min at room
temperature. After staining, samples were subjected to cytofluorimetric analysis by using the BD
FACSJazz™ Cell Sorter (Becton Dickinson).
2.8. Mitochondrial Membrane Potential Analysis
To measure mitochondrial membrane potential, cells were stained with the CM-H2TMRos
probe (MitoTracker Orange, ThermoFisher), whose accumulation in mitochondria is dependent upon
membrane potential, according to the manufacturer’s protocols. Briefly, 1 × 105 cells/well were seeded
in 6-well plates and treated with 50 nM thioalbamide or DMSO for 72 h. After treatment, cells
were harvested, rinsed, and incubated in 10 nM MitoTracker Orange solution in PBS for 30 min at
37 ◦C. After staining, cells were fixed with 3.7% formaldehyde in PBS at 37 ◦C for 15 min, rinsed,
and resuspended in PBS. Samples were then subjected to cytofluorimetric analysis by using the BD
FACSJazz™ Cell Sorter (Becton Dickinson). Cells incubated with 2 µM FCCP for 30 min were used as a
positive control for mitochondrial membrane potential reduction.
2.9. Reactive Oxygen Species (ROS) Assessment
1× 105 MCF7 cells/well were seeded in 6-well plates and treated with 50 nM thioalbamide or DMSO
for 24/72 h. Cells treated with 1 mM H2O2 for 6 h were used as the positive control. After treatment, cells
were washed with PBS, collected, resuspended in 5 µM CM-H2DCFDA (ThermoFisher Scientific) in
PBS, and incubated for 45 min at 37 ◦C. Stained cells were collected by centrifugation, and resuspended
in fresh pre-chilled medium. Finally, the fluorescence of samples was quantified with a fluorimeter
(Synergy H1 microplate reader, BioTek, Winooski, VT, USA), and fluorescence intensity was normalized
by viable cell number (TC20 automated cell counter, Bio-Rad).
2.10. ROS-Scavenging Assay
To evaluate if thioalbamide cytotoxicity was mediated by oxidative stress, cells were treated with
50 nM thioalbamide in the presence or absence of 1 mM vitamin E or 600 µM N-acetyl cysteine (NAC)
for 72 h. After treatment, cell viability was assessed by the MTT assay, as described above in the cell
viability section.
2.11. Superoxide Dismutase Activity Assay
Superoxide dismutase activity was assessed on total cell lysates (50 µg of proteins) by using a
colorimetric SOD assay kit (Sigma Aldrich) as per the manufacturer’s instructions. This is an indirect
assay method based on xanthine oxidase mediated production of superoxide anion that is able to
reduce 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium salt
(WST-1) in a water-soluble formazan dye. SOD activity, which neutralizes superoxide anions, inhibits
WST-1 reduction and dye formation that can quantified by monitoring absorbance at 450 nm using a
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microplate reader (Synergy H1 microplate reader, BioTek). SOD1 enzyme (Sigma-Aldrich) was used as
a standard.
2.12. Seahorse XFe96 Metabolic Profile Analysis
Real-time oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) rates
for cells treated with thioalbamide were determined using the Seahorse Extracellular Flux (XFe96)
analyzer (Seahorse Bioscience, USA) to assess mitochondrial and glycolytic function, respectively.
The analysis was performed as previously described [16]. Briefly, 1 × 104 cells per well were seeded
into XFe96 well cell culture plates, and incubated overnight to allow for cell attachment. Then, cells
were treated with thioalbamide (50 nM and 100 nM) for 48 h. Vehicle alone (DMSO) control cells were
processed in parallel. After 48 h of incubation, cells were washed in pre-warmed XF assay media (or
for OCR measurement, XF assay media supplemented with 10 mM glucose, 1 mM Pyruvate, 2 mM
l-glutamine, and adjusted at pH 7.4). Cells were then maintained in 175 µL/well of XF assay media
at 37 ◦C in a non-CO2 incubator for 1 h. During the incubation time, we loaded 25 µL of 80 mM
glucose, 9 µM oligomycin, and 1 M 2-deoxyglucose (for ECAR measurement) or 10 µM oligomycin,
9 µM FCCP, 10 µM rotenone, 10 µM antimycin A (for OCR measurement) in the XF assay media into
the injection ports in the XFe96 sensor cartridge. Measurements were normalized by protein content
(SRB assay). Datasets were analyzed using XFe96 software and GraphPad Prism software through
one-way ANOVA and Student’s t-test calculations. All experiments were performed in quintuplicate,
three times independently.
2.13. Mammosphere Formation Assay
A single cell suspension was prepared using enzymatic (1x Trypsin-EDTA, Sigma Aldrich), and
manual disaggregation (25 gauge needle). Cells were seeded at a density of 5000 cells/well in a
mammosphere medium (DMEM-F12 + B27 supplement + 20 ng/mL EGF + penicillin/streptomycin)
under non-adherent conditions in 6-well plates pre-coated with (2-hydroxyethylmethacrylate)
(poly-HEMA, Sigma Aldrich). Then, cells were treated with thioalbamide at concentrations ranging
from 25 nM to 100 nM. Vehicle alone (DMSO) treated cells were processed in parallel as a control.
Cells were grown for five days and maintained in a humidified incubator at 37 ◦C. After five days of
culture, 3D-spheres >50 µm were counted using an eye piece (“graticule”), and the percentage of cells
plated that formed spheres was calculated and is referred to as the percent mammosphere formation
efficiency (MFE).
2.14. ALDEFLUOR Assay
The levels of ALDH enzymatic activity in cell sub-populations were assessed using the fluorescent
reagent ALDEFLUOR kit (StemCell Technologies, Durham, NC, USA) by FACS (SONY SH800). Briefly,
1 × 105 cells were incubated in 1 mL ALDEFLUOR assay buffer containing ALDH substrate (5 µL/mL)
for 40 min at 37 ◦C. Cells isolated from mammospheres were trypsinized and syringed twice with
a 25G needle before incubation and analysis. For each experiment, a sample of cells was stained
under identical conditions in the presence of 30 µM diethylaminobenzaldehyde (DEAB), a specific
ALDH inhibitor, as a negative control. The ALDH-positive population was established according to
the manufacturer’s instructions and evaluated using 50,000 cells (for adherent cells) and 30,000 (for
mammospheres). All of the ALDH experiments were performed three times independently.
2.15. CD44 Expression
CD44 expression was evaluated in cells in grown in adherent conditions as well as from cells
isolated from mammospheres. For adherent conditions, 1 × 105 cells were treated with 50 nM
thioalbamide for 72 h in 6-well plates, grown as a monolayer. Cells were spun down and incubated
with the CD44 antibody (APC mouse Anti-Human CD44, BD Pharmingen cat. 559942) for 15 min on
ice in DPBS Ca2+/Mg2+. For mammosphere conditions, cells derived from mammospheres were spun
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down and syringed twice in the presence of trypsin 0.5% using a 25G needle. 1 × 105 MCF7 cells were
incubated with the CD44 (APC mouse Anti-Human CD44, BD Pharmingen cat. 559942) antibody for
15 min on ice in DPBS Ca2+/Mg2+. Samples were analyzed by FACS (SONY SH800) and data were
analyzed using FlowJo software.
2.16. Statistical Analysis
Data are presented as the mean values ± standard deviation, taken over ≥3 independent
experiments, with ≥3 replicates per experiment, unless otherwise stated. Statistical significance was
measured by using the analysis of variance (ANOVA) test. A P value ≤ 0.05 was considered statistically
significant. Non-linear regression analysis (GraphPad Prism 7) was used to generate sigmoidal
dose-response curves to calculate the IC50 values.
3. Results
3.1. Thioalbamide Affects Cell Viability of Several Breast Cancer Cellular Lines
The antiproliferative effects of thioalbamide were evaluated over a wide range of breast cancer
cell lines characterized by differences in the status of the three main receptors conventionally used for
breast cancer subtyping: estrogen receptor (ER), progesterone receptor (PR), and human epithelial
receptor 2 (HER2) [17]. In particular, we evaluated the effects of thioalbamide on the viability of
luminal cell lines MCF7 and T47D in the HER2 positive cell line SKBR3 and in triple-negative cell lines
MDA-MB-231 and MDA-MB-468. Thioalbamide showed a significant inhibitory effect on the viability
of all lines tested. The IC50 values, calculated for each experimental model after 72 h of treatment, were
all in a range between 54 and 75 nM (Table 1). The effects on cell viability were significantly higher
than the clinically used doxorubicin (IC50 values ranging from 154 nM to 1.17 µM), and were notably
independent of the receptor profile of mammary tumor cells.
Table 1. Cytotoxic activity of thioalbamide in comparison to doxorubicin a.
Cell Line Doxorubicin Thioalbamide
MCF7 b
IC50 (µM) 0.878 0.059
95% confidence interval 0.723 to 1.071 0.049 to 0.072
MDA-MB-231 b
IC50 (µM) 1.174 0.072
95% confidence interval 0.938 to 1.477 0.058 to 0.088
MDA-MB-468
IC50 (µM) 0.362 0.054
95% confidence interval 0.259 to 0.504 0.043 to 0.069
T47D
IC50 (µM) 0.536 0.075
95% confidence interval 0.380 to 0.756 0.061 to 0.092
SKBR3
IC50 (µM) 0.154 0.074
95% confidence interval 0.108 to 0.221 0.056 to 0.097
MCF 10A b
IC50 (µM) 0.343 0.302
95% confidence interval 0.253 to 0.464 0.206 to 0.444
BJ-hTERT IC50 (µM) 0.360.5 0.321
95% confidence interval 0.269 to 0.484 0.215 to 0.474
a Data are presented as IC50 values (µM) and 95% confidence intervals obtained by nonlinear regression analysis of
three independent experiments. b Results reported in [1].
Importantly, thioalbamide did not exert any effects on the viability of the non-malignant breast
epithelial cell line MCF10A and the normal fibroblast cell line BJ-H, at concentrations toxic for
cancer cells. As reported in Table 1, the IC50 value for MCF10A cells was up to 6-fold higher than
those for the tumor cell lines, highlighting thioalbamide’s specificity for the malignant phenotype.
Since thioalbamide has shown to possess anti-viability activity at very similar concentrations in all
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tumor cell lines tested, independently of their tumor subtype, we decided to focus the mechanistic
studies on a single experimental model, the luminal breast carcinoma cell line MCF7.
3.2. Thioalbamide Induces Cellular Morphology Changes
First, the ability of thioalbamide to induce morphological changes in the treated cells was evaluated.
As highlighted by phase-contrast light microscopy as well as by May-Grunwald and Giemsa staining,
after 72 h of treatment, the MCF7 cell morphology was drastically altered, and the treated cells appeared
more heterogeneous in terms of shape and size. As shown in Figure 2, the untreated control cells grew
well and exhibited epithelial-like features, forming a monolayer on the plate. Conversely, the growth
of MCF7 treated with thioalbamide was reduced, and cell fusion, shrinkage, nuclear condensation, and
apoptotic bodies appeared.Cells 2019, 8, x 8 of 20 
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3.3. Thioalbamide Induces Arrest of Cell Cycle in G1 Phase
The effects of thioalbamide on viability were further investigated. In particular, the ability of
thioalbamide to alter the different phases of the cell cycle was evaluated using cytofluorimetric analysis.
As shown in Figure 3a,b, thioalbamide treatment induced a substantial decrease of cells in the S and
G2-M phases, together with the appearance of a significant hypodiploid population (sub-G1). The peak
of hypodiploid cells is generally associated with cells undergoing apoptosis, where genomic DNA
appears drastically fragmented [18,19]. These results suggest that thioalbamide treatment can block
the transition from G1 to the subsequent phases of the cell cycle, and cells accumulate in the G1 phase
before undergoing cell death.
Cells 2019, 8, x 9 of 20 
 
showed a drastic reduction in both CDKs and their respective cyclins in MCF7 cells after 72 h of 
thioalbamide treatment. Cell cycle arrest in the G1 phase was also confirmed by the 
dephosphorylation and activation of Retinoblastoma protein (Rb), an oncosuppressor able to bind to 
the E2F transcription factor family [22,23], inhibiting their function and DNA replication. 
 
Figure 3. Thioalbamide inhibits cell cycle progression. (a) Cytofluorimetric analysis of MCF7 cells 
treated for 72 h with DMSO (control) or 50 nM thioalbamide and stained with PI; graphs represent 
the percentage of total events in the samples (highlighting the sub-G1 peak). (b) Cell cycle distribution 
of MCF7 cells (excluding sub-G1 events). (c) Immunoblot analysis of the main regulators of G1/S 
phase transition and quantification of their expression levels by densitometry. Note that thioalbamide 
treatment induces cell cycle arrest at the G1/S checkpoint. Values represent mean ± SD of three 
independent experiments. **** P value < 0.0001. 
3.4. Thioalbamide Induces Cell Death by Activation of both Extrinsic and Intrinsic Apoptotic Pathways 
Thioviridamide, the first identified molecule of the TLMs family, is known to induce cell death 
through apoptotic processes [4]. This knowledge, together with the evidence that thioalbamide 
treatment is able to enrich the hypodiploid cell population, has led us to investigate whether the 
trigger of apoptosis is a common feature of thioviridamide-like molecules. For this purpose, MCF7 
cells were treated with thioalbamide and subjected to different assays, each one specific for a different 
event of the apoptotic pathway. The TUNEL assay was performed to highlight the ability of 
thioalbamide to induce DNA fragmentation, a late event in apoptosis. As shown in Figures 4a and 
S6, after 72 h of treatment, the percentage of TUNEL-positive cells was elevated, which is consistent 
with the increased population of hypodiploid cells observed in the cell cycle. 
. fl i
f r 72 h with DMSO (control) or 50 nM thioalbamide and stained with PI; graphs rep sent the
percentage of t tal events in the samples (highlighting the sub-G1 peak). (b) Cel cycle
f ll ( l i - t ). ( ) I l t l sis f t i l t f /
s tr siti tific ti f t ir r ssi l ls sit tr . t t t t i l i
tr t t i c s c ll c cl rr st t t e 1/S checkpoint. l s r r s t f t r
i e e e t ex eri e ts. **** al e 0.0001.
These results were confirmed by the immunoblotting analysis of several proteins involved in the
G1-S transition (Figure 3b,c) such as cyclins E and D1 as well as their respective cyclin-dependent
kinase (CDK2 and CDK4), with which they are able to form active complexes [20,21]. Our findings
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showed a drastic reduction in both CDKs and their respective cyclins in MCF7 cells after 72 h of
thioalbamide treatment. Cell cycle arrest in the G1 phase was also confirmed by the dephosphorylation
and activation of Retinoblastoma protein (Rb), an oncosuppressor able to bind to the E2F transcription
factor family [22,23], inhibiting their function and DNA replication.
3.4. Thioalbamide Induces Cell Death by Activation of both Extrinsic and Intrinsic Apoptotic Pathways
Thioviridamide, the first identified molecule of the TLMs family, is known to induce cell death
through apoptotic processes [4]. This knowledge, together with the evidence that thioalbamide
treatment is able to enrich the hypodiploid cell population, has led us to investigate whether the trigger
of apoptosis is a common feature of thioviridamide-like molecules. For this purpose, MCF7 cells were
treated with thioalbamide and subjected to different assays, each one specific for a different event of
the apoptotic pathway. The TUNEL assay was performed to highlight the ability of thioalbamide to
induce DNA fragmentation, a late event in apoptosis. As shown in Figure 4a and Figure S6, after
72 h of treatment, the percentage of TUNEL-positive cells was elevated, which is consistent with the
increased population of hypodiploid cells observed in the cell cycle.
Next, Annexin V assay was performed to monitor the externalization of phosphatidylserine on
the outer leaflet of the cell membrane. This event characterizes the early stage of apoptosis and, in
physiological conditions, facilitates apoptotic cells recognition from macrophages and destruction
of apoptotic bodies [24,25]. Interestingly, 24 h of thioalbamide treatment were sufficient for 80% of
the treated cells to enter an early stage of apoptosis (Figure 4b). In order to definitively confirm the
induction of the apoptotic process, the ability of thioalbamide to determine a loss of mitochondrial
membrane potential and the release of cytochrome C, normally confined within mitochondria, into
the cytosol were evaluated. The loss of mitochondrial membrane potential represents the “point of
no-return” in the apoptotic process. Indeed, this event is responsible for a change in mitochondrial
membrane permeability and leads to the translocation into the cytoplasm of cytochrome C that, by
forming apoptosome complex, triggers the apoptotic cascade of caspases [26]. After treatment, MCF7
cells showed a significant reduction in mitochondrial membrane potential with respect to untreated
cells (Figure 4c, Figure S9). Moreover, immunoblotting analysis of cytochrome C levels in the cytosolic
fraction confirmed that thioalbamide induced cytochrome C release, with a concomitant reduction of
cytochrome C found into the mitochondrial fraction (Figure 4d,e). Finally, it was decided to evaluate the
cleavage and activation of procaspases -8 and -9, initiator caspases involved in extrinsic and intrinsic
apoptosis pathways respectively [27]. Immunoblot analysis revealed that thioalbamide treatment
induced the activation of both pathways in MCF7 cells (Figure 4f,g).
In order to understand if the apoptotic mechanisms induced by thioalbamide observed in MCF7
cells, are also underlying the cytotoxic effects observed in the other breast cancer cells, TUNEL assay
was performed in MDA-MB-231, MDA-MB-468, T47D and SKBR3 cells treated with thioalbamide.
Our results indicate that thioalbamide induces cell death via apoptosis in all tested breast cancer cell
lines (Figures S2–S6).
3.5. Oxidative Stress Underlies the Cytotoxic Effects of Thioalbamide
In order to better understand the mechanisms underlying thioalbamide-induced apoptosis, the
levels of reactive oxygen species (ROS) produced in untreated and treated MCF7 cells were assessed
by cytofluorimetric analysis. ROS are well known biochemical mediators of apoptosis as they are
strongly reactive toward several biological macromolecules, particularly toward proteins involved
in the electro-chemical equilibrium of the mitochondrial membrane [28]. Interestingly, thioalbamide
induced a significant 2-fold increase in ROS levels after 24 h of treatment, and ROS reached a 4-fold
increase after 72 h of treatment, relative to the control cells (Figure 5a).
Cells 2019, 8, 1408 10 of 19
Cells 2019, 8, x 11 of 20 
 
 
Figure 4. Thioalbamide induces cell death by activation of both extrinsic and intrinsic apoptotic 
pathways. (a) TdT-mediated dUTP nick-end-labeling (TUNEL) assay in MCF7 cells treated for 72 h 
with vehicle (Ctrl) or thioalbamide. DAPI was used for DNA staining (scale bar: 50 μm). (b) Annexin 
V-PI assay was performed to detect apoptosis in DMSO-treated cells (Ctrl) and cells treated with 
thioalbamide for 24 h; histograms represent the percentage of cell populations after treatment. (c) Loss 
Figure 4. i al a i e i ces cell eat acti ation of both extrinsic and intrinsic apoptotic
pathways. (a) - e iate ic -e -la eling (T NEL) assay in MCF7 cells treated for 72 h
with vehicle (Ctrl) or thioalba ide. I as se for staining (scale bar: 50 µm). (b) Annexin
Cells 2019, 8, 1408 11 of 19
V-PI assay was performed to detect apoptosis in DMSO-treated cells (Ctrl) and cells treated with
thioalbamide for 24 h; histograms represent the percentage of cell populations after treatment. (c) Loss
of mitochondrial membrane potential after 72 h of thioalbamide treatment was assessed using a
MitoTracker Orange CM-H2TMRos probe. (d) Release of cytochrome C into the cytosolic and
mitochondrial fractions of cells treated for 72 h with thioalbamide was assessed by immunoblot analysis.
GAPDH and COX4 were used as equal loading controls of the cytosolic and mitochondrial fractions,
respectively. (e) Quantification of cytochrome C levels in the cytosolic and mitochondrial fractions
by densitometry. (f) Immunoblot analysis of pro-caspases 8 and 9 after 24 and 72 h of treatment
with thioalbamide. GAPDH was used as the equal loading control. (g) Quantification of pro-caspase
expression levels by densitometry. All thioalbamide treatments were performed at 50 nM. Note that
thioalbamide treatment triggers early and late events of apoptosis, involving both intrinsic and extrinsic
pathways. Values represent the mean ± SD of three independent experiments. * P value < 0.05;
** P value < 0.01; **** P value < 0.0001.Cells 2019, 8, x 13 of 20 
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were measured after thioalbamide treatment of MCF7 cells for 24 and 72 h. Results obtained from
cells treated for 6 h with 1 mM H2O2, which was used as the positive control, were related to their
own control. (b) MCF7 cell viability was assessed after treatment for 72 h with thioalbamide alone or
in combination with vitamin E (Vit E) or N-acetyl cysteine (NAC). (c) Total SOD activity assay was
performed on MCF7 cells treated with thioalbamide for 24 and 72 h. (d) Immunoblot analysis of SOD1
and SOD2 expression levels in MCF7 cells treated with thioalbamide for 24 and 72 h. GAPDH was used
as equal loading control. (e) Quantification of SOD expression levels by densitometry. Thioalbamide
treatments were performed at 50 nM. Note that ROS acc mulation and oxidative stress underlie
the proapoptotic activ ty of thioalbamide Values repr sent the mean ± SD of three independent
experiments. *** P value < 0.001; **** P value < 0.0001.
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In order to confirm that oxidative stress is responsible for thioalbamide-induced cytotoxicity, a
viability assay was performed on MCF7 treated with thioalbamide alone and in the presence of a
ROS scavenger such as vitamin E and N-acetyl cysteine. After 72 h of treatment, no cytotoxicity was
detected in the thioalbamide-scavenger co-treated cells (Figure 5b), confirming that oxidative stress is
the event responsible for the induction of apoptosis and cytotoxicity. The same result was obtained in
all of the other cancer cell lines tested, demonstrating that oxidative stress induced by thioalbamide is
responsible for the cytotoxic effects observed in all of the different breast cancer cell lines used in this
study (Figure S7).
In order to understand whether thioalbamide-induced ROS accumulation is due to an effective
increase in ROS production or to a deficiency of the ROS neutralization system, the expression levels
and activity of superoxide dismutases (SODs) were evaluated in MCF7 cells treated with thioalbamide.
The SOD family of enzymes are specifically responsible for the neutralization of superoxide anion (.O2−),
one of the main sub-products of cellular metabolism that originates from an incomplete reduction of
molecular oxygen in the mitochondrial respiratory chain [29]. Interestingly, SOD activity was increased
by >2 folds in cells treated with thioalbamide for 72 h as a physiological response to the increased
ROS production (Figure 5c). However, the increase in SOD activity was not sufficient to balance the
time-dependent ROS accumulation induced by thioalbamide treatment.
There are several isoforms of SOD that are specific for different cellular compartments [30]. Thus,
immunoblotting analysis of the different SOD isoforms was performed in order to understand whether
the increase in SOD activity observed was specific to a cellular compartment. Figure 5d–e showed that
thioalbamide treatment increased the expression of SOD2, the mitochondrial isoform, while the levels
of SOD1, the cytoplasmic isoform, were found to be unaltered. These results indicate an increase in
ROS production at the mitochondrial level [31], suggesting an important involvement of mitochondria
in thioalbamide’s mechanism of action.
3.6. Thioalbamide Treatment Affects Glycolysis and Mitochondrial Respiration
It is known that the production of ROS is closely related to cellular energy metabolism [32].
Therefore, the ability of thioalbamide treatment to alter the breast cancer cell metabolic profile
was evaluated by assessing mitochondrial respiration and glycolytic function by using a Seahorse
XFe96 analyzer.
Mitochondrial function was assessed by monitoring oxygen consumption rate (OCR), and
sequentially, injections of oligomycin, FCCP, and an antimycin/rotenone mix allowed us to evaluate
mitochondrial function parameters such as basal respiration, maximal respiration, ATP production,
proton leak, and spare respiratory capacity. Interestingly, MCF7 cells treated with thioalbamide for
48 h displayed a dramatic reduction of all mitochondrial respiration parameters (Figure 6a,b), which is
consistent with the above-mentioned reduction in mitochondrial membrane potential (Figure 4c).
Glycolytic function was assessed by monitoring extracellular acidification rate (ECAR), and
sequentially, injections of glucose, oligomycin, and 2-deoxy-D-glucose (2-DG) allowed us to evaluate
the glycolytic function parameters. Notably, MCF7 cells treated with thioalbamide for 48 h showed
significantly reduced glycolysis and glycolytic capacity, while the glycolytic reserve was affected only
at higher concentrations (Figure 6c,d). Similar results with the metabolic profile and mitochondrial
membrane potential were obtained in the other breast cancer lines tested (Figures S8 and S9),
emphasizing once again that the effects induced by thioalbamide are similar in all breast cancer cell
lines, independent of their subtype and biological heterogeneity.
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Overall, our results highlight the ability of thioalbamide to inhibit energy metabolism of
breast cancer cells, affecting the two main pathways of cell metabolism: glycolysis and oxidative
phosphorylation. These effects result in a significant change in the metabolic phenotype of cancer cells
from a highly energy status to a quiescent one.
3.7. Thioalbami e Affects B ast Ca r Stem Cells Propagation
In recent years, much focus has been given to the identification of molecules that are able to inhibit
cancer stem cells (CSCs), the sub-population of tumor cells responsible for therapy resistance and
tumor recurrence. Since mitochondrial function is required for anchorage-independent survival and
propagation of cancer stem-like cells [33], and considering that thioalbamide strongly reduces cancer
cell mitochondrial function, we investigated if thioalbamide may affect cancer stem cells. To this end,
we monitored mammosphere formation efficiency (MFE) as well as two validated CSC markers, the
activity of aldehyde dehydrogenase (ALDH) and the expression of CD44 antigen. The results obtained
indicate that thioalbamide is able to reduce, in a dose-dependent manner, mammosphere formation
efficiency in all the cell lines tested (Figure 7a,b) as well as the ALDH+ population in MCF7-derived
spheroids (Figure 7c) and CD 44 expression in adherent cells and mammospheres (Figure 7d and
Figure S10). These results demonstrate a significant inhibition of breast cancer stem cells, confirming
thioalbamide inhibitory effects on cell metabolism and opening new scenarios regarding the use of this
natural product in the oncologic field.
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Figure 7. Thioalbamide inhibits CSCs propagation. (a) Mammosphere formation efficiency assay was
performed on breast cancer cells (MCF7, T47D, SKBR3, MDA-MB-231, and MDA-MB-468) after treatment
for five days with 25 nM, 50 nM, and 100 nM thioalbamide. All breast cancer cells tested showed a
significant dose dependent reduction in mammosphere for ation after treatment with thioalbamide.
Mammospheres were grown in n -atta hment condition and counted using an Olympus BX41 (4×
magnification) microscope. 3D-spheres >50 µm were counted using an eye piece (“graticul ”), and the
percentage of cells plated that formed spheres was calculated and referred to as percent mammosphere
formation efficiency (MFE). (b) Representative images of MCF7 cell mammospheres. Scale bar: 125 µm.
(c) CD44 expression and (d) ALDH activity were chosen as CSC markers. Anti-human CD44-APC
antibodies and (d) an ALDEFLUOR assay kit were used to stain MCF7 cells. Samples were analyzed
using a SONY SH800 cell sorter. A significant reduction of CD44-positive cells and ALDH-positive
cells was detected after treatment with 50 nM of thioalbamide in MCF7 cells grown in no-attachment
(mammospheres) conditions. Values represent the mean ± SD of three independent experiments.
ns = not significant; * P value < 0.05; ** P value <0.01; *** P value < 0.001; **** P value < 0.0001.
4. Discussion
Since the discovery of penicillin by Alexander Fleming in 1928, microbial-derived natural products
have been an essential resource for the development of new pharmacological agents [34]. Within the
wide variability of microorganisms populating terrestrial and marine ecosystems, bacteria belonging
to the phylum Actinobacteria are the main source of natural bioactive molecules [35,36]. Indeed, the
secondary metabolism of these microorganisms is complex and extremely variable, and is responsible
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for the production of very different molecules from a chemical, biosynthetic. and biological activity
point of view [2,37–39].
Thioviridamide-like molecules are a family of thioamided peptides with a high antitumor
potential that appear to be highly conserved, despite the profound variability between the amino
acid sequence of the different family members [8]. Although in recent years various advances have
been made on the identification of new TLMs [7] and in understanding the biosynthetic pathways
underlying their production in Actinobacteria [40,41], no study has so far been carried out to elucidate
the molecular and cellular mechanisms underlying their enormous pharmacological potential. Herein,
a biochemical-metabolic approach was used to investigate in different breast cancer cell lines the
mechanism of action of thioalbamide, a TLM, which in previous studies has demonstrated a strong
cytotoxic activity highly specific toward malignant phenotypes [1].
In this study, we used a large panel of breast cancer cells to reflect the biological diversity of the
different breast cancer subtypes, characterized by a different response to traditional chemotherapy,
endocrine therapy, and immunotherapy [42,43]. Despite the effectiveness of these therapeutic
approaches and their widespread use, the onset of resistance and recurrence remains an unmet clinical
need, driving the continuous research for alternative pharmaceutical approaches. Our results, obtained
on MCF7, T47D, SKBR3, MDA-MB-231, and MDA-MB-468 cells, underline the independence of the
thioalbamide mode of action from the receptor status of the tumor cells, highlighting the profound
versatility of this microbial natural peptide.
Using microscopy, cytofluorimetric, and immuno-detection analysis, we demonstrated that
thioalbamide induced cell cycle arrest in the G1 phase and cell death by intrinsic and extrinsic apoptotic
mechanisms. Pro-apoptotic effects had been previously evidenced for thioviridamide [4], the first TLM
identified, and our results confirm that these mechanisms are common among different members of
the family. This evidence suggests that, despite the variability of the amino acid residues that make up
these metabolites, the conserved chemical characteristics of these natural products lie at the basis of
their enormous antitumor potential. The arrest of the cell cycle in the G1 phase, moreover, suggests
that thioalbamide can affect the normal physiological processes of the cell [44] that does not meet the
replicative processes and subsequently dies.
In addition, we discovered that an increase in ROS production is the trigger for
thioalbamide-induced apoptotic cell death. Excessive increase in intracellular ROS levels induced by
thioalbamide treatment greatly affects mitochondrial function. Indeed, breast cancer cells respond to
thioalbamide-induced oxidative stress with a selective increase in the activity and expression levels
of the mitochondrial isoform of superoxide dismutase (SOD2), an enzyme normally responsible for
neutralizing superoxide anions, the main sub-products of cellular respiration.
Since ROS are generated by cellular metabolism, their accumulation and consequent oxidative
stress are often associated with alterations to metabolic pathways [45]. Metabolic reprogramming
is one of the characteristics of cancer, since tumors require catabolites to produce ATP, maintain a
redox balance, and generate biomass. Depending on the availability of nutrients, some cells within
the tumor are predominantly glycolytic, while others have a phenotype dependent on oxidative
phosphorylation. Since the metabolic reprogramming of tumor cells accelerates energy metabolism
to support the high proliferation rate of malignant neoplasms [46], metabolic processes represent an
important pharmacological target for cancer therapy. Therefore, in this work, the energy profile of
cells treated with thioalbamide was also evaluated, and the results highlight the ability of this natural
product to inhibit the two main cellular energy pathways: glycolysis and oxidative phosphorylation.
It is known that under physiological conditions, a reduction in mitochondrial respiration leads to a
compensatory increase in glycolytic metabolism, which is fundamental for maintaining cellular energy
requirements [47,48]. However, in our experimental conditions, the thioalbamide effects are consistent
with what has been reported in other studies, showing that OXPHOS inhibitors [49] and oxidative
stress inducers [50] generate only a temporary spike of glycolytic metabolism, while a prolonged
exposure to such chemicals causes a drastic reduction of the extracellular acidification rate.
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Moreover, we show here that thioalbamide can inhibit the growth and propagation of cancer
stem-like cells (CSCs), the subpopulation of tumor cells mainly responsible for cancer resistance,
recurrence, and metastasis. CSCs are characterized by a metabolic profile that differentiates them from
bulk tumor cells and healthy stem cells. Indeed, CSCs have a high metabolic flexibility that allows
them to switch between the glycolytic and phosphorylative pathways, according to the energy needs of
the malignant cell. Indeed, our results indicate that thioalbamide may eradicate CSCs by targeting their
energy metabolism and reducing the metabolic flexibility responsible for their tumorigenicity [51–53].
As such, the effects of thioalbamide on CSCs opens new avenues in the application of this
microbial natural product in cancer therapy. Further studies will be needed to better delineate the exact
molecular mechanism underlying the biological activity of thioalbamide and TLMs. Furthermore,
in vivo pharmacokinetic and pharmacodynamic studies are indispensable to further explore the
promising potential of this new family of microbial natural products in more complex experimental
models to validate the potential use of thioalbamide in clinical settings.
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